Artificial intelligence (AI) is one of the exciting ingredients in Captario’s design and decision support for drug development. Knowledge, of course, is another.
“The big pharmaceutical companies keep an eye on each other. Nobody wants to be first, but once one of them has embraced something new, the interest from the others increases significantly. That’s why it meant so much when Novartis showed so much interest,” says Johannes Vänngård, CEO.